author-photo

Susan J. McCall

Memorial Sloan Kettering Cancer Center

15

Papers

359

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

2017 Blood
Show All
- Source
- Cite
- Save
Citations (65)
BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.

2016 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (19)
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

2016 Blood
Show All
- Source
- Cite
- Save
Citations (49)
Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588

2016 Blood
Show All
- Source
- Cite
- Save
Citations (2)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (153)
Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation

2015 Blood
Show All
- Source
- Cite
- Save
Citations (2)
TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

2015 Blood
Show All
- Source
- Cite
- Save
Citations (8)